Trump set to reclassify cannabis for medical research potential

Hold onto your hats, folks—President Donald Trump is poised to shake up federal drug policy with a bold move on cannabis reclassification.

This executive order, expected to be signed soon, aims to shift cannabis from Schedule I to Schedule III, easing barriers to medical research while stopping short of full federal legalization, as NBC News reports.

Currently, cannabis sits in the Schedule I category under the Controlled Substances Act of 1970, lumped in with heavy hitters like heroin and LSD, implying no medical value and high abuse potential. This classification has long stifled scientific study, leaving researchers handcuffed by red tape.

Breaking Down Barriers to Research

Trump’s anticipated order would fast-track a change to Schedule III, a less restrictive category that could finally let the FDA dive into cannabis’s medical possibilities. It’s a pragmatic step for an administration often skeptical of overreaching bureaucracy.

The President has signaled his intent, noting the need to unlock research currently blocked by outdated rules. “We are considering that because a lot of people want to see it — the reclassification, because it leads to tremendous amounts of research that can’t be done unless you reclassify,” Trump said. Well, if breaking down needless barriers isn’t a win for common sense, what is?

This isn’t a free-for-all, though—federal legalization isn’t on the table with this move. The order simply nudges the DEA or Attorney General Pam Bondi to wrap up a rescheduling process that’s been dragging since last year due to administrative delays.

Pushing for Broader Policy Shifts

There’s also talk of the order nudging Congress to pass the SAFER Banking Act, which would let cannabis businesses access financial services instead of operating in a shady cash-only limbo. It’s a practical fix for an industry caught in legal purgatory.

Another potential directive could push Medicare and Medicaid to cover CBD products, a small but meaningful nod to patients seeking alternatives. For conservatives wary of government overreach, this balances compassion with restraint.

Trump’s recent meetings with cannabis executives and officials like Dr. Marty Makary, Robert F. Kennedy Jr., and Dr. Mehmet Oz show he’s not just tossing out ideas—he’s listening. It’s a far cry from the progressive agenda that often ignores real-world input.

Critics and Advocates Weigh In

Not everyone’s cheering, of course, with Sen. Ron Wyden slamming the move as insufficient. “Trump will try to gaslight everyone into believing he just made pot legal,” Wyden posted on X. Sorry, Senator, but this isn’t about legalizing anything—it’s about research, not reefer madness.

Wyden’s critique pushes for decriminalization and expunging records for minor drug offenses, a broader reform that misses the point of this targeted policy. While thousands remain behind bars for cannabis crimes from the 1990s war on drugs, this order isn’t pretending to solve every issue overnight.

Advocacy groups like the Last Prisoner Project are also in the mix, urging clemency alongside policy shifts. It’s a fair ask—justice delayed is justice denied—but let’s not pretend one executive order can rewrite decades of bad policy.

Public Support and Conservative Balance

Public sentiment leans heavily toward reform, with a Gallup poll showing 64% of Americans backing legal marijuana use. That’s a loud message, even for conservatives who prioritize law and order over cultural fads.

Trump’s recent signing of rules to regulate low-THC hemp products shows he’s not ignoring the broader cannabis landscape either. It’s a measured approach, avoiding the chaos of unchecked liberalization favored by some on the left.

At the end of the day, this executive order could mark a turning point for cannabis policy, blending conservative caution with a nod to medical progress. It’s not perfect, but it’s a step away from the nanny-state nonsense that’s held back research for too long. Let’s hope the momentum keeps rolling.